Phase-Appropriate GMP: Building QMS for Clinical Trials

Most quality management systems are designed backward from commercial manufacturing. They assume stable processes, validated equipment, predictable batch volumes, and a regulatory dossier that's mostly finished. Clinical trial material (CTM) manufacturing runs on almost the opposite assumptions — and that mismatch is where compliance programs quietly come apart.

In my view, this is one of the more underappreciated problems in drug development. Organizations that build excellent quality infrastructure for their commercial products frequently discover, sometimes painfully, that those same systems create serious friction in the clinic. Too much overhead slows the iteration pace that early-phase development demands. Too little structure creates documentation gaps that shadow the program for years.

What CTM manufacturing actually needs is a QMS that holds two things in tension: the rigor of GMP and the flexibility of R&D. Most systems optimize for one or the other. The ones that manage both are worth understanding carefully.

What Makes Clinical Trial Material Manufacturing Different

The fundamental difference between CTM manufacturing and commercial manufacturing is purpose. Commercial manufacturing produces product for patients who depend on consistent quality, batch over batch, for years. CTM manufacturing produces product to answer a question — does this molecule do what we think it does, at what dose, with what safety profile?

That question-answering purpose changes almost everything about how the quality system should work.

Batch sizes in Phase 1 are tiny. Formulations change, sometimes dramatically, between cohorts. Analytical methods evolve alongside the molecule. Process parameters that will be tightly characterized in Phase 3 are deliberately exploratory in Phase 1 — the manufacturing team is making documented decisions to operate outside a commercial design space that doesn't yet exist.

The stakes of getting this wrong compound over time. According to the Tufts Center for the Study of Drug Development, the average cost of bringing a new drug to market now exceeds $2.6 billion when accounting for the cost of failures. A significant portion of that number traces back to manufacturing and CMC-related setbacks. FDA data suggests manufacturing and CMC issues account for approximately 30% of clinical holds placed on IND applications — and in most of those cases, the underlying cause isn't bad science. It's documentation gaps, inadequate change control, and quality systems that weren't calibrated to what early-phase work actually requires.

That's a problem with an architectural solution. And the architecture is what this article is about.

What "Phase-Appropriate" Actually Means

The phrase "phase-appropriate compliance" appears constantly in regulatory guidance around CTM manufacturing. I think it's worth sitting with what it actually means, because it's commonly misread.

It doesn't mean less rigorous. That misreading creates real problems — teams in Phase 1 treat quality requirements as optional, then arrive in Phase 2 unable to reconstruct the manufacturing history that regulators expect to see. What phase-appropriate actually means is that the evidence required to demonstrate control scales with the stage of development and the risk to trial subjects. A Phase 1 program manufacturing 200 vials of an oncology candidate isn't held to the same process validation standards as a Phase 3 program producing 50,000 units. But the deviation investigation, the change control documentation, the batch record — those fundamentals apply from day one.

Here's how the QMS requirements landscape shifts across development phases:

The table tells a story worth internalizing: the QMS doesn't suddenly appear at Phase 3. It grows incrementally, phase by phase, adding rigor as the program matures and the evidence base deepens. Organizations that treat their early-phase QMS as a placeholder to be replaced later — rather than a foundation to be built upon — tend to have the most painful NDA-readiness experiences.

Where Most QMS Platforms Fall Short

Most commercially available quality systems were built to support either large pharma commercial operations or small teams doing basic document control. Neither profile fits the typical CTM manufacturing environment, and I think it's worth being specific about why.

The commercial-grade overkill problem. Enterprise QMS platforms often require weeks of administrative work to initiate and close a single change control record. When your formulation team is iterating on a solubilization approach every two weeks in Phase 1, that kind of workflow overhead doesn't just slow things down — it creates perverse incentives. Teams start working around the system, making informal decisions that should be documented, because the formal process is too cumbersome to use in real time. The quality system meant to protect the program ends up undermining it.

The under-built startup problem. On the other end, clinical-stage companies sometimes implement a QMS that amounts to a shared folder with labeled subfolders and a list of SOPs stored in a word processor. That can pass an early audit when the auditor is generous with a small program, but it collapses quickly under the weight of Phase 2 — when you're managing a growing deviation log, multiple CMO relationships, and regulatory inquiries that require traceable documentation going back eighteen months.

The gap between these two failure modes is significant. A 2023 survey by the Parenteral Drug Association found that approximately 58% of clinical-stage biotechs reported their QMS created measurable delays in manufacturing cycle time. That's a majority of the field dealing with a problem that is structural, not scientific.

The middle path — a QMS calibrated specifically to CTM manufacturing — requires adaptive change control workflows, robust batch record management without commercial-scale overhead, and deviation tracking that connects to risk management rather than living as an isolated silo. That combination is harder to find than it should be.

The Five GMP Pressure Points in CTM Manufacturing

If I were mapping where compliance gaps most often materialize in a clinical-stage manufacturing program, I'd focus attention on five areas. These aren't theoretical vulnerabilities — they're where documented failures cluster.

1. Starting material and raw material controls. The traceability chain for clinical materials needs to run cleanly from raw material receipt through final product release. This is harder than it sounds when you're sourcing novel excipients, working with a reference standard that exists in quantities measured in grams, or relying on a supplier whose material specifications aren't commercially established. Your QMS needs to handle partial lot usage, retest dating for small-volume materials, and documentation for components that may only appear in one or two batches before the formulation evolves past them.

2. Master batch record version control. In early-phase CTM manufacturing, the master batch record is often a living document — reflecting a process under active development. That's scientifically legitimate. But it requires version control discipline that organizations consistently underestimate. Programs have been derailed by investigators who couldn't reconstruct which version of a process was running for which batch, because the QMS treated the MBR as a static document rather than an evolving one. Version control isn't bureaucracy in this context — it is the audit trail.

3. Change control across program evolution. This is the area where phase-appropriate thinking gets most abused. Teams treat Phase 1 as a change-control-free zone — moving quickly, reasonably, but without documentation — and then find themselves in Phase 2 or Phase 3 unable to explain the formulation's development history in terms regulators can follow. Every material change in the manufacturing process, even in Phase 1, needs to live in the change control system with documented rationale. The depth of impact assessment scales with phase. The documentation requirement does not.

4. Deviation and out-of-specification management. A well-designed CTM deviation system distinguishes between three categories: deviations that might affect subject safety, deviations that might affect data integrity, and deviations that are process learning events. Many QMS platforms treat all deviations identically, forcing teams into extensive documentation exercises for minor procedural issues while sometimes under-resourcing the genuinely critical ones. Building risk stratification into the deviation workflow itself — not as a manual judgment call each time, but as a systematic triage — is one of the higher-leverage design decisions in a CTM quality system.

5. CMO oversight and the extended quality system. Most clinical-stage organizations don't own manufacturing capacity. They work with contract manufacturing organizations, contract testing labs, and specialty suppliers across a supply chain that may span multiple countries and regulatory jurisdictions. The quality system needs to extend across that network through quality agreements, audit programs, batch record review protocols, and technology transfer documentation. The expectation from regulators is that quality oversight doesn't stop at the sponsor's office door. The QMS infrastructure has to make that extended oversight manageable at the scale of a lean quality team.

What a CTM-Ready QMS Actually Looks Like

A QMS built for clinical trial manufacturing has characteristics that distinguish it from both the heavy commercial platforms and the lightweight startup implementations.

It supports adaptive workflows. Change control has tiered tracks — expedited review for low-risk changes, full impact assessment for changes that touch formulation, process, or specifications. Teams can move quickly on routine decisions without waiting for a committee; the system escalates when the risk threshold demands it. This isn't a lower bar — it's an intelligently placed one.

It connects quality events to risk. Deviations, out-of-specification results, and supplier issues feed into a living risk register rather than sitting in isolated queues. When a new deviation comes in, the investigator can see what other events have touched this material, this process step, or this CMO. Pattern recognition across quality events is one of the most underutilized capabilities in early-phase programs. The data exists; a connected QMS makes it visible.

It grows with the program. A Phase 1 QMS configuration is genuinely different from a Phase 3 configuration, but both should live in the same system with the same core data model. That continuity matters enormously at regulatory transition points. When you're preparing a Phase 3 IND amendment or a pre-NDA briefing package, the ability to pull clean, continuous quality data from the first Phase 1 batch through the latest Phase 3 lot is worth months of program time compared to reconstructing that history from fragmented records.

It supports distributed teams. The quality unit at a clinical-stage company is often physically separated from manufacturing, sometimes by thousands of miles. QMS platforms that require on-site access or that don't support remote review and approval with appropriate security controls create bottlenecks that delay batch release and push out program timelines in ways that are entirely preventable.

A 2022 analysis by Deloitte Life Sciences found that companies with integrated digital quality platforms experienced an average 22% reduction in batch release cycle time compared to companies using paper-based or fragmented QMS approaches. In a clinical program, that kind of efficiency gain isn't just operational — it translates directly into program timeline and the capital required to reach the next value inflection.

What the Regulatory Framework Expects

Regulatory agencies have been increasingly direct about their expectations for CTM manufacturing quality systems. The ICH Q10 pharmaceutical quality system framework describes a PQS that applies across the product lifecycle — from development through commercial manufacturing — and explicitly addresses the unique characteristics of development-phase work.

What I find useful about the ICH Q10 framing is its emphasis on the quality system as a mechanism for continuous improvement, not just a compliance checkpoint. In the CTM context, that means using deviation investigations to actually improve the process, using change control data to understand where formulation instabilities live, using OOS trending to anticipate analytical challenges before they become batch failures. The quality data your system generates should be informing manufacturing decisions, not just documenting them.

The FDA's lifecycle approach to process validation aligns with this. Phase 1 manufacturing isn't expected to look like commercial manufacturing — the expectation is that the quality infrastructure established in Phase 1 will scale intelligently into Phase 2 and Phase 3, with each phase adding the evidence appropriate to the program's maturity and risk profile. Organizations that build toward that trajectory from the beginning, rather than treating early-phase quality as a placeholder, create a compounding advantage. The data continuity problem alone — trying to reconstruct three years of manufacturing history from records scattered across disconnected systems — can delay regulatory submissions by months and adds significant cost that serves no scientific purpose.

The Real Question to Ask

The way I've come to think about QMS for CTM manufacturing is this: your quality system is making a bet about what kind of program you're going to be running. A system optimized for minimum overhead bets that problems will be small and containable. A system optimized for maximum documentation assumes all problems are equally critical. Neither bet fits a clinical program.

What you actually need is a quality system that makes intelligent bets — applying intensive oversight where the risk to subjects and data is real, moving quickly where it can, and building the data infrastructure to demonstrate, at any point in the development arc, that you understand your process and your controls.

The programs that get this right don't just pass audits. They generate better manufacturing data, catch problems earlier, and enter regulatory conversations with the kind of quality narrative that moves things forward rather than stalling them.

If you're building or rebuilding a CTM quality program, the starting question isn't "what does GMP require?" It's "what does my manufacturing process need to tell me so I can run a clean program through all three phases?" Your QMS should be the system that answers that question — and grows alongside the program it supports.

Explore how Nova QMS supports phase-appropriate quality management for clinical-stage organizations, or read more about QMS design for small biotechs and growing quality teams.

Last updated: 2026-07-22